Neonatal Multimorbidity is a Poor Predictor of Health and Developmental Outcomes after Preterm Birth

Jonathan S Litt1, Mandy B Belfort2, Erika M Edwards3

  • 1Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA.

The Journal of Pediatrics
|December 14, 2025
PubMed

Insights

Neonatal multimorbidity is common in extremely low birth weight infants, but current models have modest predictive ability for 24-month outcomes. Further research is needed to improve prognostic accuracy for this vulnerable population.

Area of Science:

  • Neonatalogy
  • Pediatric Outcomes Research
  • Biostatistics

Background:

  • Extremely low birth weight (ELBW) infants face significant health challenges.
  • Neonatal morbidities are common in ELBW infants and impact long-term development.
  • Predictive models are crucial for identifying high-risk ELBW infants.

Purpose of the Study:

  • To evaluate and compare the predictive capabilities of three multimorbidity-based models.
  • To assess the prediction of early childhood outcomes in infants born with ELBW.
  • To identify the most effective model for predicting developmental delay, rehospitalization, and therapeutic service use.

Main Methods:

  • Analysis of 8332 surviving ELBW infants from the Vermont Oxford Network (2010-2020).
  • Inclusion of neonatal morbidities such as bronchopulmonary dysplasia, intraventricular hemorrhage, and necrotizing enterocolitis.
  • Comparison of three gestational age-adjusted risk models: morbidity count, specific morbidity count, and latent classes.

Main Results:

  • Thirty-five percent of ELBW infants experienced two or more neonatal morbidities.
  • Morbidity counts and latent classes were associated with increased risk for adverse 24-month outcomes.
  • All three models demonstrated modest predictive ability (AUC = 0.66).

Conclusions:

  • Neonatal multimorbidity is prevalent in ELBW infants and linked to later outcomes.
  • Current diagnosis-based multimorbidity risk models have limited prognostic value.
  • Improved characterization of multimorbidity is essential for enhancing clinical utility.
Abstract